Company intelligence / Profile preview

Zhejiang Xinghao Pengbo Pharmaceutical

Zhejiang Sheng, China

Ownership: Private
Development stage: Other

Overview

Zhejiang Xinghao Pengbo Pharmaceutical is a subsidiary of Shanghai Fosun Pharmaceutical, focused on developing novel small molecule drugs for metabolic and immune-related diseases. Its lead programs target complement-mediated kidney diseases and respiratory disorders. As of June 2025, the company has two main clinical-stage assets—one in Phase 2 for non-cystic fibrosis bronchiectasis and another entering Phase 1 for IgA nephropathy[1][3][4].

Therapeutic areas: NephrologyPulmonology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

XH-S002

Partnerships

Shanghai Henlius Biotech(for technical services/CMC/preclinical work on FS2101 antibody drug)[7]

Beyond the preview

Go deeper on Zhejiang Xinghao Pengbo Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Xinghao Pengbo Pharmaceutical.